NEW YORK, Aug. 6 – Qiagen on Monday reported a 24 percent surge in second-quarter revenues from the same period one year ago as demand for the company’s nucleic acid reagents and research tools continued to climb.

Revenue for the quarter ended June 30 totaled $66.0 million, up from $53.3 million during the second quarter 2000. Net earning for the recent period came in at $11.3 million, or 8 cents per share, compared with $1.8 million, or 1 cent er share, year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.